The ghrelin receptors (GHS-R1a and GHS-R1b)

Endocrine Development

Volumn 25, Issue , 2013, Pages 5-15

  Albarrán Zeckler, Rosie G ^a   Smith, Roy G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMORELIN; DOPAMINE RECEPTOR; GHRELIN; GHRELIN RECEPTOR;

AGING; ARTICLE; BRAIN REGION; CACHEXIA; CARDIOVASCULAR SYSTEM; GLUCOSE HOMEOSTASIS; GROWTH HORMONE RELEASE; HUMAN; MALNUTRITION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84877993565     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000346042     Document Type: Article

References (63)

1. Diano S, et al: Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 2006; 9: 381-388.
2. Sun Y, Asnicar M, Smith RG: Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology 2007; 86: 215-228.
3. Andrews ZB, et al: Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci 2009; 29: 14057-14065.
4. Albarran-Zeckler RG, Sun Y, Smith RG: Physiological roles revealed by ghrelin and ghrelin receptor deficient mice. Peptides 2011; 32: 2229-2235.
5. Dixit VD, et al: Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007; 117: 2778-2790.
6. Abizaid A, et al: Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 2006; 116: 3229-3239.
7. Albarran-Zeckler RG, Brantley AF, Smith RG: Growth hormone secretagogue receptor (GHS-R1a) knockout mice exhibit improved spatial memory and deficits in contextual memory. Behav Brain Res 2012; 232: 13-19.
8. Garcia JM, Friend J, Allen S: Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129-137.
9. Egecioglu E, et al: Ghrelin increases intake of rewarding food in rodents. Addict Biol 2010; 15: 304-311.
10. Jiang H, Betancourt L, Smith RG: Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 2006; 20: 1772-1785.
11. Kern A, et al: Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 2012; 73: 317-332.
12. Milligan G: G protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today 2006; 11: 541-549.
13. Smith RG, et al: Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Rec Prog Horm Res 1996; 51: 261-286.
14. Smith RG, et al: A nonpeptidyl growth hormone secretagogue. Science 1993; 260: 1640-1643.
15. Bowers CY, et al: On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-1545.
16. Smith RG, et al: Mechanism of action of GHRP-6 and nonpeptidyl growth hormone secretagogues; in Bercu BB, Walker RF (eds): Growth Hormone Secretagogues, Serono Symposia. New York, Springer, 1996, pp 147-163.
17. Howard AD, et al: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
18. Honda K, et al: An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus. Neuroscience 1999; 90: 875-883.
19. Liu B, Garcia EA, Korbonits M: Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O -acyl transferase (GOAT) genes. Peptides 2011; 32: 2191-2207.
20. Kojima M, et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
21. Yang J, et al: Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387-396.
22. Gutierrez JA, et al: Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA 2008; 105: 6320-6325.
23. Kirchner H, et al: Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. Am J Physiology Endocrinol Metab 2010; 298:E909-E919.
24. Nakazato M, et al: A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
25. Smith RG, et al: A new orphan receptor involved in pulsatile growth hormone release. Trends Endocrinol Metab 1999; 10: 128-135.
26. Leung PK, et al: The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal 2007; 19: 1011-1022.
27. Chow KB, et al: The truncated ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression. Mol Cell Endocrinol 2012; 348: 247-254.
28. Nagaya N, et al: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1483-R1487.
29. Sun Y, et al: Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology 2008; 149: 843-850.
30. Tesauro M, et al: Metabolic and cardiovascular effects of ghrelin. Int J Pept 2010; 2010 pii:864342.
31. Svensson J, et al: Two-Month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998; 83: 362-369.
32. Chapman IM, et al: Stimulation of the growth hormone (GH)-insulin-like growth factor-I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-4257.
33. Sun Y, et al: Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 2004; 101: 4679-4684.
34. Zigman JM, et al: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115: 3564-3572.
35. Sun Y, et al: Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006; 3: 379-386.
36. Muzzin P, et al: Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci USA 1996; 93: 14804-14808.
37. Cowley MA, et al: The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649-661.
38. Ellis J, et al: Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 2006; 281: 38812-38824.
39. Rediger A, et al: Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. J Biol Chem 2011; 286: 39623-39631.
40. Ortiz O, et al: Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci 2010; 30: 12288-12300.
41. Wellman PJ, Hollas CN, Elliott AE: Systemic ghrelin sensitizes cocaine-induced hyperlocomotion in rats. Regul Pept 2008; 146: 33-37.
42. Jerlhag E, et al: The alcohol-induced locomotor stimulation and accumbal dopamine release is suppressed in ghrelin knockout mice. Alcohol 2011; 45: 341-347.
43. Jerlhag E, et al: Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference. Psychopharmacology (Berl) 2010; 211: 415-422.
44. Wei YH, et al: Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Ann NY Acad Sci 1998; 854: 155-170.
45. Massaad CA: Neuronal and vascular oxidative stress in Alzheimer's disease. Curr Neuropharmacol 2011; 9: 662-673.
46. Moon M, et al: Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 2009; 15: 332-347.
47. Jiang H, et al: Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 2008; 212: 532-537.
48. Richard D, et al: Uncoupling protein 2 in the brain: distribution and function. Biochem Soc Trans 2001; 29: 812-817.
49. Chung H, et al: Ghrelin suppresses tunicamycin- or thapsigargin-triggered endoplasmic reticulum stress-mediated apoptosis in primary cultured rat cortical neuronal cells. Endocr J 2011; 58: 409-420.
50. Chow KB, Cheng CH, Wise H: Anti-inflammatory activity of ghrelin in human carotid artery cells. Inflammation 2009; 32: 402-409.
51. Enomoto M, et al: Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 2003; 105: 431-435.
52. Nagaya N, et al: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-1435.
53. Palus S, et al: Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One 2011; 6:e26865.
54. Klocke R, et al: Surgical animal models of heart failure related to coronary heart disease. Cardiovasc Res 2007; 74: 29-38.
55. Nagaya N, et al: Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-3679.
56. Garcia JM, et al: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920-2926.
57. Nagaya N, et al: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104: 2034-2038.
58. Garcia JM, et al: Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008; 149: 455-460.
59. Dixit VD, et al: Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
60. Adunsky A, et al: MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011; 53: 183-189.
61. Baldanzi G, et al: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-1037.
62. Filigheddu N, et al: Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 2007; 18: 986-994.
63. Caminos JE, et al: The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. Endocrinology 2005; 146: 1285-1292.